Genmab A/S (GNMSF)
USD 203.33
(0.0%)
USD 203.33
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 5.56 Billion DKK | -19.81% |
| 2022 | 7.04 Billion DKK | 103.38% |
| 2021 | 3.46 Billion DKK | -48.74% |
| 2020 | 6.75 Billion DKK | 133.21% |
| 2019 | 2.77 Billion DKK | 89.25% |
| 2018 | 1.46 Billion DKK | 5.18% |
| 2017 | 1.45 Billion DKK | 29.21% |
| 2016 | 1.09 Billion DKK | 40.89% |
| 2015 | 585.98 Million DKK | 153.12% |
| 2014 | 277.5 Million DKK | 188.36% |
| 2013 | 80.91 Million DKK | 230.8% |
| 2012 | -96.24 Million DKK | 44.8% |
| 2011 | -192.74 Million DKK | -145.61% |
| 2010 | -61.76 Million DKK | 73.51% |
| 2009 | -77.1 Million DKK | 58.64% |
| 2008 | -516.45 Million DKK | -91.57% |
| 2007 | -317.72 Million DKK | 29.22% |
| 2006 | -419.7 Million DKK | -18.6% |
| 2005 | -360.46 Million DKK | -165.22% |
| 2004 | 537.45 Million DKK | 13.25% |
| 2003 | 474.55 Million DKK | -29.14% |
| 2002 | 669.75 Million DKK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.1 Billion DKK | 149.25% |
| 2024 Q1 | 1.09 Billion DKK | -50.23% |
| 2023 Q3 | 1.96 Billion DKK | 14.89% |
| 2023 Q1 | 629 Million DKK | -77.58% |
| 2023 FY | - DKK | -19.81% |
| 2023 Q2 | 1.7 Billion DKK | 171.22% |
| 2023 Q4 | 1.96 Billion DKK | 0.26% |
| 2022 FY | - DKK | 103.38% |
| 2022 Q2 | 2.68 Billion DKK | 388.91% |
| 2022 Q1 | 550 Million DKK | -34.83% |
| 2022 Q3 | 2.02 Billion DKK | -24.58% |
| 2022 Q4 | 2.8 Billion DKK | 38.31% |
| 2021 FY | - DKK | -48.74% |
| 2021 Q4 | 844 Million DKK | -39.76% |
| 2021 Q3 | 1.4 Billion DKK | 64.44% |
| 2021 Q2 | 852 Million DKK | 43.43% |
| 2021 Q1 | 594 Million DKK | 564.06% |
| 2020 Q3 | 1.39 Billion DKK | -69.35% |
| 2020 FY | - DKK | 133.21% |
| 2020 Q4 | -128 Million DKK | -109.2% |
| 2020 Q2 | 4.53 Billion DKK | 3952.68% |
| 2020 Q1 | 112 Million DKK | -94.94% |
| 2019 Q3 | 350.73 Million DKK | 155.7% |
| 2019 Q2 | 137.16 Million DKK | 3042.87% |
| 2019 Q1 | -4.66 Million DKK | -100.63% |
| 2019 Q4 | 2.21 Billion DKK | 531.34% |
| 2019 FY | - DKK | 89.25% |
| 2018 Q2 | 135.04 Million DKK | -59.86% |
| 2018 Q1 | 336.45 Million DKK | -52.86% |
| 2018 FY | - DKK | 5.18% |
| 2018 Q4 | 739.62 Million DKK | 269.49% |
| 2018 Q3 | 200.17 Million DKK | 48.23% |
| 2017 FY | - DKK | 29.21% |
| 2017 Q4 | 713.79 Million DKK | 1124.34% |
| 2017 Q2 | 536.41 Million DKK | 1064.35% |
| 2017 Q3 | 58.3 Million DKK | -89.13% |
| 2017 Q1 | 46.07 Million DKK | -93.59% |
| 2016 Q3 | 186.83 Million DKK | 31.78% |
| 2016 FY | - DKK | 40.89% |
| 2016 Q4 | 718.46 Million DKK | 284.54% |
| 2016 Q1 | 52.33 Million DKK | -86.36% |
| 2016 Q2 | 141.78 Million DKK | 170.89% |
| 2015 Q1 | 182.3 Million DKK | 154.04% |
| 2015 Q3 | 142.67 Million DKK | 261.97% |
| 2015 Q2 | 39.41 Million DKK | -78.38% |
| 2015 Q4 | 383.58 Million DKK | 168.84% |
| 2015 FY | - DKK | 153.12% |
| 2014 Q3 | 139.32 Million DKK | 539.37% |
| 2014 FY | - DKK | 188.36% |
| 2014 Q4 | 71.76 Million DKK | -48.49% |
| 2014 Q2 | -31.71 Million DKK | -130.26% |
| 2014 Q1 | 104.8 Million DKK | 74.51% |
| 2013 Q3 | 4.69 Million DKK | 126.3% |
| 2013 FY | - DKK | 230.8% |
| 2013 Q2 | -17.86 Million DKK | -148.23% |
| 2013 Q1 | 37.04 Million DKK | 6043.28% |
| 2013 Q4 | 60.05 Million DKK | 1178.04% |
| 2012 Q1 | -40.56 Million DKK | -284.66% |
| 2012 Q4 | 603 Thousand DKK | 102.68% |
| 2012 FY | - DKK | 44.8% |
| 2012 Q2 | -33.82 Million DKK | 16.6% |
| 2012 Q3 | -22.46 Million DKK | 33.6% |
| 2011 Q1 | -57.6 Million DKK | -1081.9% |
| 2011 Q3 | -54.31 Million DKK | 12.02% |
| 2011 Q2 | -61.73 Million DKK | -7.17% |
| 2011 FY | - DKK | -145.61% |
| 2011 Q4 | 21.96 Million DKK | 140.44% |
| 2010 Q4 | -4.87 Million DKK | -102.83% |
| 2010 Q2 | -88.06 Million DKK | 37.52% |
| 2010 Q1 | -140.93 Million DKK | -345.99% |
| 2010 FY | - DKK | 73.51% |
| 2010 Q3 | 172.11 Million DKK | 295.45% |
| 2009 Q1 | -10.66 Million DKK | 0.0% |
| 2009 FY | - DKK | 58.64% |
| 2009 Q3 | -126.67 Million DKK | 17.27% |
| 2009 Q4 | 57.29 Million DKK | 145.23% |
| 2009 Q2 | -153.1 Million DKK | -1335.2% |
| 2008 FY | - DKK | -91.57% |
| 2007 FY | - DKK | 29.22% |
| 2006 FY | - DKK | -18.6% |
| 2005 FY | - DKK | -165.22% |
| 2004 FY | - DKK | 13.25% |
| 2003 FY | - DKK | -29.14% |
| 2002 FY | - DKK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 7928.425% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 93894.659% |
| SQZ Biotechnologies Company | -64.14 Million USD | 8769.961% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 32114.968% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -5813.559% |
| Mesoblast Limited | -62.38 Million USD | 9013.324% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 362132.722% |
| Genus plc | 73.7 Million USD | -7445.455% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 84210.802% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 156880.466% |
| Marizyme, Inc. | -34.28 Million USD | 16321.591% |
| ContraFect Corporation | -64.99 Million USD | 8655.516% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 63494.893% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 122962.581% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 396801.973% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 210389.633% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 239404.249% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 1073556.797% |
| Accustem Sciences Inc. | -3.74 Million USD | 148535.079% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 11630.885% |
| EV Biologics, Inc. | -1.26 Million USD | 438965.091% |
| Q BioMed Inc. | -617.62 Thousand USD | 900480.164% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -155583.091% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 879440.171% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 243524.241% |
| Biomind Labs Inc. | -1.03 Million USD | 537628.914% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | -56202.521% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 77753.77% |
| Skye Bioscience, Inc. | -13.54 Million USD | 41148.012% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 373970.858% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 22244100.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 143265.342% |
| IMV Inc. | -35.52 Million USD | 15754.472% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 35141.538% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 222365.566% |
| GB Sciences, Inc. | -1.41 Million USD | 391751.437% |
| Alpha Cognition Inc. | -9.7 Million USD | 57396.812% |
| HST Global, Inc. | -5303.00 USD | 104865270.658% |
| CSL Limited | 4.78 Billion USD | -16.12% |
| Halberd Corporation | -74.27 Thousand USD | 7486738.215% |
| Enzolytics Inc. | -2.12 Million USD | 262160.509% |
| Resverlogix Corp. | -11.74 Million USD | 47459.905% |
| Affymax, Inc. | -14.29 Million USD | 39001.717% |
| SYBLEU INC | -141.57 Thousand USD | 3928164.363% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 181653.084% |
| argenx SE | -216.02 Million USD | 2674.262% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 10148.971% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -456843.303% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 371103.919% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -1467786.518% |
| AVAX Technologies, Inc. | -6.11 Million USD | 91075.377% |
| Zenith Capital Corp. | -8.6 Million USD | 64717.709% |
| Genscript Biotech Corporation | -248.71 Million USD | 2335.852% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 31921344.475% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 227407.936% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 3159321.826% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 14129.871% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 192367.4% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 531585.828% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -82703647.769% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 317871.61% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 289598.056% |
| BioStem Technologies, Inc. | -7.55 Million USD | 73720.087% |
| ONE Bio Corp. | 13.61 Million USD | -40750.525% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 3070982.665% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 270445.163% |
| Agentix Corp. | -1.37 Million USD | 405492.796% |
| LadRx Corporation | 412.28 Thousand USD | -1348730.779% |
| Cell Source, Inc. | -4.27 Million USD | 130257.195% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 1514446.946% |
| Regen BioPharma, Inc. | 1.46 Million USD | -379242.9% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 593622.166% |
| NovAccess Global Inc. | -1.03 Million USD | 537500.089% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -62709.182% |
| Itoco Inc. | -1.86 Million USD | 297639.587% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 1464985.939% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 498397.491% |
| Kadimastem Ltd | -2.62 Million USD | 211997.587% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 2325418.838% |
| CytoDyn Inc. | -18.02 Million USD | 30944.75% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 7036757.43% |
| Mobile Lads Corp. | -2.24 Million USD | 248230.543% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 45473973.579% |
| Qrons Inc. | -40.08 Thousand USD | 13874504.331% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 1145097.303% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -1054251.927% |
| Rebus Holdings, Inc. | -951 Thousand USD | 584852.892% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 523729.721% |
| International Stem Cell Corporation | 202 Thousand USD | -2752870.297% |
| Bioxytran, Inc. | -3.82 Million USD | 145670.314% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 10564309.726% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 225979.513% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 15603.638% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 12357877.778% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 203204.456% |
| Neutra Corp. | -181.24 Thousand USD | 3068288.715% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 27685.694% |
| PureTech Health plc | -11.62 Million USD | 47928.331% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 27687.585% |
| IXICO plc | -707 Thousand USD | 786662.942% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 72461.744% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 11602.503% |
| CSL Limited | 4.73 Billion USD | -17.494% |
| Cellectis S.A. | -92.63 Million USD | 6103.066% |